| Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy L Zhai, S Spranger, DC Binder, G Gritsina, KL Lauing, FJ Giles, ... Clinical cancer research 21 (24), 5427-5433, 2015 | 289 | 2015 |
| IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma E Ladomersky, L Zhai, A Lenzen, KL Lauing, J Qian, DM Scholtens, ... Clinical cancer research 24 (11), 2559-2573, 2018 | 165 | 2018 |
| Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival L Zhai, E Ladomersky, KL Lauing, M Wu, M Genet, G Gritsina, B Győrffy, ... Clinical Cancer Research 23 (21), 6650-6660, 2017 | 146 | 2017 |
| Activation of MAPK signaling by CXCR7 leads to enzalutamide resistance in prostate cancer S Li, K Fong, G Gritsina, A Zhang, JC Zhao, J Kim, A Sharp, W Yuan, ... Cancer research 79 (10), 2580-2592, 2019 | 103 | 2019 |
| Targeted blockade of JAK/STAT3 signaling inhibits ovarian carcinoma growth G Gritsina, F Xiao, SW O'Brien, R Gabbasov, MA Maglaty, RH Xu, ... Molecular cancer therapeutics 14 (4), 1035-1047, 2015 | 98 | 2015 |
| The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy L Zhai, M Dey, KL Lauing, G Gritsina, R Kaur, RV Lukas, MK Nicholas, ... Journal of Clinical Neuroscience 22 (12), 1964-1968, 2015 | 67 | 2015 |
| Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma L Zhai, E Ladomersky, CR Dostal, KL Lauing, K Swoap, LK Billingham, ... Brain, behavior, and immunity 62, 24-29, 2017 | 54 | 2017 |
| HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer X Lu, K Fong, G Gritsina, F Wang, SC Baca, LT Brea, JE Berchuck, ... Nature genetics 54 (5), 670-683, 2022 | 48 | 2022 |
| Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer G Gritsina, WQ Gao, J Yu Asian journal of andrology 21 (3), 215-223, 2019 | 30 | 2019 |
| Advanced age negatively impacts survival in an experimental brain tumor model E Ladomersky, L Zhai, G Gritsina, M Genet, KL Lauing, M Wu, CD James, ... Neuroscience letters 630, 203-208, 2016 | 28 | 2016 |
| Improving vaccine efficacy against malignant glioma E Ladomersky, M Genet, L Zhai, G Gritsina, KL Lauing, RR Lulla, ... Oncoimmunology 5 (8), e1196311, 2016 | 15 | 2016 |
| FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A X Wang, L Brea, X Lu, G Gritsina, SH Park, W Xie, JC Zhao, J Yu Oncogene 41 (37), 4259-4270, 2022 | 7 | 2022 |
| CXCR7 as a novel therapeutic target for advanced prostate cancer G Gritsina, J Yu Oncogene 42 (11), 785-792, 2023 | 5 | 2023 |
| The kynurenine/tryptophan ratio and glioblastoma patients treated with Hsppc-96 vaccine A Lenzen, L Zhai, KL Lauing, G Gritsina, E Ladomersky, M Genet, ... Immunotherapy (Los Angeles, Calif.) 2 (3), 2016 | 5 | 2016 |
| Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth G Gritsina, K Fong, X Lu, Z Lin, W Xie, S Agarwal, D Lin, GE Schiltz, ... The Journal of Clinical Investigation 133 (15), 2023 | 1 | 2023 |
| Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer S Li, K Fong, G Gritsina, A Zhang, JC Zhao, J Kim, A Sharp, W Yuan, ... Cancer Research 80 (10), 2072-2072, 2020 | 1 | 2020 |
| Nuclear localization of immunosuppressive IDO1 in cancer: a paradigm‐shift to the tryptophan depletion theory GA Gritsina, L Zhai, ER Ladomersky, J Qian, KL Lauing, TM Bui, ... The FASEB Journal 31, 747.4-747.4, 2017 | 1 | 2017 |
| THU479 FOXA1 Loss Remodels The Tumor Immune Microenvironment In Late-stage Prostate Cancer LT Brea, H Shi, V Keo, W Xie, X Lu, G Gritsina, X Wang, SH Park, J Zhao, ... Journal of the Endocrine Society 7 (Supplement_1), bvad114. 2107, 2023 | | 2023 |
| Atypical Chemokine Receptor CXCR7 Signaling and Prostate Cancer Progression GA Gritsina Northwestern University, 2023 | | 2023 |
| Abstract LB032: CXCR7 drives prostate cancer growth through AURKA activation G Gritsina, Z Lin, KW Fong, X Lu, C Zhao, J Yu Cancer Research 82 (12_Supplement), LB032-LB032, 2022 | | 2022 |
